Introgen Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. Introgen is developing molecular therapeutics, immunotherapies, vaccines and nano-particle tumor suppressor therapies a wide spectrum of a broad spectrum of cancers with tumor suppressors, cytokines and genes. Introgen maintains integrated research, development, manufacturing, clinical and regulatory departments and operates multiple manufacturing facilities including a commercial scale cGMP manufacturing facility.
To Introgen ADVEXIN Phase 3 study results Present At American Association For Cancer Research Cancer Clinical TrialsIntrogen Therapeutics, Inc. , a developer of targeted molecular therapies for cancer, announced that the company will present the results of its recently completed Phase 3 trial of ADVEXIN in recurrent head and neck cancer at the American Association for Cancer Research Centennial Conference on Translational Cancer Medicine 2008: cancer Clinical Trials and Personalized Medicine.The scientists now speculate to by newly discovered mutation, the structure of the Gjf1 channel protein is modified, small Jochen Graw : mutant a roman connexin-like Generated in the the mouse Influences morning Lens history and cause a variable of small – eye phenotypes. Investigative Ophthalmology & Visual Science, pp. 1525-1532.
– in patients of Asian ancestry in other ETHNIC . Stated Dr. The KRAS gene – a gene in which EGFR signaling – at in 8 % cases of lung , but in none with detecting EGFR activating mutations. The mutation was common in men, Caucasians, and current or former Designated Smoking.